Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Q BioMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q BioMed Initiates Rapid Development of Novel COVID-19 Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q BioMed Announces Initiation of GMP Production of Novel COVID-19 Therapeutic for Clinical Trial Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q BioMed's Uttroside-B Receives Additional Patent Coverage in Canada and Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Clionix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Q BioMed Signs License Agreement with Clionix for the Distribution and Sales of Strontium89 in Europe and Middle East","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Q BioMed","sponsor":"isoSolutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Q BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Mannin Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q BioMed Inc. Updates on COVID-19 Therapeutic Development and Clinical Trials - MAN-19 Therapeutic Program Heading to Clinical Trial in Early 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Chengdu Syncor Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Q BioMed Announces Initial $500k Order of Strontium89 to Chinese Market","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q Biomed Announces Publication of Research Showing Augmented Efficacy of Its Drug Candidate Uttroside-b Against Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Oklahoma Medical Research Foundation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q Biomed Announces Publication of Pre-clinical Research Showing Superior Safety and Efficacy Against Current First Line Therapy of Its Drug Candidate Uttroside-B for Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Mannin Research","pharmaFlowCategory":"D","amount":"$42.3 million","upfrontCash":"Undisclosed","newsHeadline":"Q Biomed Announces Addition Of Multi-Million Dollar Asset Value With Equity Stake In Maniin Research Inc.","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Q BioMed

    Menu

    Q BioMed

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Q BioMed

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Q Biomed Announces Addition Of Multi-Million Dollar Asset Value With Equity Stake In Maniin Research Inc.

              Details:

              By utilizing MRI’s internal pro-forma revenue projections for 2023 & 2024 and comparable market transactions, MRI’s drug development pipeline including MAN-01 and companion diagnostics, are estimated to achieve a net present value.

              Lead Product(s): MAN-01

              Therapeutic Area: Ophthalmology Product Name: MAN-01

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Mannin Research

              Deal Size: $42.3 million Upfront Cash: Undisclosed

              Deal Type: Agreement November 14, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Q BioMed

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Q Biomed Announces Publication of Pre-clinical Research Showing Superior Safety and Efficacy Against Current First Line Therapy of Its Drug Candidate Uttroside-B for Liver ...

              Details:

              Present study attests to previous report that Uttroside-B is pharmacologically safe up to five times IC50 dose in acute and sub-chronic toxicity models, while even IC50 dose of sorafenib is toxic to immunocompromised mice, and elevated doses of sorafenib adverse effects.

              Lead Product(s): Uttroside B

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Oklahoma Medical Research Foundation

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 26, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Q BioMed

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Q Biomed Announces Publication of Research Showing Augmented Efficacy of Its Drug Candidate Uttroside-b Against Liver Cancer

              Details:

              In the initial Scientific Reports study, researchers showed that in animal models, Uttroside-B was ten times more cytotoxic to the HepG2 liver cancer cell line than sorafenib, the only drug approved by the FDA for liver cancer approved at the time.

              Lead Product(s): Uttroside B

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 16, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Q BioMed

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Q BioMed Announces Initial $500k Order of Strontium89 to Chinese Market

              Details:

              The agreement is expected to be a high-growth opportunity to supply Strontium89 in the Chinese market. Strontium89 is FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer and is agnostic of the primary tumor.

              Lead Product(s): Strontium-89 Chloride

              Therapeutic Area: Musculoskeletal Product Name: Metastron

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Chengdu Syncor Pharmaceutical

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement March 07, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Q BioMed

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Q BioMed Inc. Updates on COVID-19 Therapeutic Development and Clinical Trials - MAN-19 Therapeutic Program Heading to Clinical Trial in Early 2022

              Details:

              MAN-19 therapeutic is a recombinant fusion protein that treats the patient, instead of targeting the virus. It is not a cure for COVID, but it strengthens a patient's blood vessels and protects them against ARDS, breathing problems, sepsis and other infections.

              Lead Product(s): MAN-19

              Therapeutic Area: Infections and Infectious Diseases Product Name: MAN-19

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Mannin Research

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Q BioMed

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Q BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada

              Details:

              Strontium89 is an FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer and is agnostic of the primary tumor.

              Lead Product(s): Strontium Chloride, Sr-89

              Therapeutic Area: Oncology Product Name: Metastron

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: isoSolutions

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement August 10, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Q BioMed

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Q BioMed Signs License Agreement with Clionix for the Distribution and Sales of Strontium89 in Europe and Middle East

              Details:

              Under the terms of the agreement, Clionix has received exclusive rights to distribute Strontium89 in Turkey, Saudi Arabia, Azerbaijan, Bulgaria, Romania, Egypt, Kuwait & Pakistan.

              Lead Product(s): Strontium Chloride, Sr-89

              Therapeutic Area: Oncology Product Name: Metastron

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Clionix

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement July 12, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Q BioMed

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Q BioMed's Uttroside-B Receives Additional Patent Coverage in Canada and Japan

              Details:

              The patent titled “Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma” is a Method Of Use patent that covers the use of Uttroside-B for the treatment of hepatocellular carcinoma (HCC).

              Lead Product(s): Uttroside B

              Therapeutic Area: Oncology Product Name: Uttroside-B

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 26, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Q BioMed

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Q BioMed Announces Initiation of GMP Production of Novel COVID-19 Therapeutic for Clinical Trial Program

              Details:

              Human and genetic studies, as well as animal models of endothelial dysfunction collectively suggest that by targeting Tie2 receptor, MAN-19 may be effective in the treatment of a number of complications associated with viral infections such as COVID-19 and seasonal flu.

              Lead Product(s): MAN-19

              Therapeutic Area: Infections and Infectious Diseases Product Name: MAN-19

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 26, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Q BioMed

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Q BioMed Initiates Rapid Development of Novel COVID-19 Therapeutics

              Details:

              The Joint venture will deploy Cyclica's unique AI platform to accelerate the development of new treatments based on Mannin's Tie2 based platform.

              Lead Product(s): COVID-19 drug

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 22, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY